A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies

Sánchez-Zuno, Gabriela Athziri; Matuz-Flores, Mónica Guadalupe; González-Estévez, Guillermo; Nicoletti, Ferdinando; Turrubiates-Hernández, Francisco Javier; Mangano, Katia; Muñoz‐Valle, José Francisco

doi:10.1177/20587384211050199

Cited by 38 publications

(45 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(2) immune complex-mediated-inflammation through complement activation and recruitment of inflammatory and immune cells (ADE via enhanced immune activation) [53];…”

Section: Discussionmentioning

confidence: 99%

Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody

Thavorasak

Chulanetra

Glab-ampai

et al. 2022

Viruses

View full text Add to dashboard Cite

Porcine epidemic diarrhea virus (PEDV) causes devastating enteric disease that inflicts huge economic damage on the swine industry worldwide. A safe and highly effective PEDV vaccine that contains only the virus-neutralizing epitopes (not enhancing epitope), as well as a ready-to-use PEDV neutralizing antibody for the passive immunization of PEDV vulnerable piglets (during the first week of life) are needed, particularly for PEDV-endemic farms. In this study, we generated monoclonal antibodies (mAbs) to the recombinant S1 domain of PEDV spike (S) protein and tested their PEDV neutralizing activity by CPE-reduction assay. The mAb secreted by one hybrodoma clone (A3), that also bound to the native S1 counterpart from PEDV-infected cells (tested by combined co-immunoprecipitation and Western blotting), neutralized PEDV infectivity. Epitope of the neutralizing mAb (mAbA3) locates in the S1A subdomain of the spike protein, as identified by phage mimotope search and multiple sequence alignment, and peptide binding-ELISA. The newly identified epitope is shared by PEDV G1 and G2 strains and other alphacoronaviruses. In summary, mAbA3 may be useful as a ready-to-use antibody for passive immunization of PEDV-susceptible piglets, while the novel neutralizing epitope, together with other, previously known protective epitopes, have potential as an immunogenic cocktail for a safe, next-generation PEDV vaccine.

show abstract

“…(2) immune complex-mediated-inflammation through complement activation and recruitment of inflammatory and immune cells (ADE via enhanced immune activation) [53];…”

Section: Discussionmentioning

confidence: 99%

Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody

Thavorasak

Chulanetra

Glab-ampai

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Information about diseases should include clear evidence of transmission, infectiousness, and the number of people who have died from the disease. Information about the vaccine should include the effectiveness of the vaccine in preventing infection, serious illness, and death, as well as possible adverse effects [ 32 ] and their probability of occurring if the vaccine is given. Moreover, there must be an expectation that the government will take responsibility for addressing adverse reactions that occur after vaccination [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Association of Vaccine Confidence and Hesitancy in Three Phases of COVID-19 Vaccine Approval and Introduction in Japan

et al. 2022

View full text Add to dashboard Cite

Understanding vaccine hesitancy, considering the target region and phase, is an urgent issue to quell the coronavirus disease (COVID-19) pandemic. This study aimed to monitor COVID-19 vaccine hesitancy in the Japanese population during the three phases of vaccine approval and introduction, and evaluate the association of vaccine hesitancy with vaccine confidence and literacy. We conducted web-based cross-sectional surveys during the three phases of COVID-19 vaccine introduction: January 2021, before approval; June, start of vaccination of the elderly; and September, when about 70% of the target population was vaccinated with at least one dose. There were 7210 participants, aged 20–80 years. We evaluated the association of vaccine hesitancy with vaccine confidence and literacy in the three phases using multivariate logistic regression analysis. The proportion of hesitancy in January, June, and September was 17.5%, 65.3%, and 19.4%, respectively. In any phase, lower vaccine confidence and literacy showed a higher adjusted odds ratio (AOR) of vaccine hesitancy in most items (AOR > 1, p < 0.001). Vaccine hesitancy in June had a different trend in perception of COVID-19 compared to that in the January and September surveys. The findings suggested that hesitancy increases transiently during vaccination introduction phases, and changes as the vaccination program progressed or waves of epidemic. Careful risk communication to increase vaccine confidence and literacy is essential to reduce vaccine hesitancy, especially in the introduction phase.

show abstract

“…For the C1q-dependent mechanism, virus-antibody C1q complexes promote fusion between the viral capsule and the cell membrane by the deposition of C1q and its receptor. This complex binds to the C1q receptor in cells, initiates the intracellular signaling pathway, and then promotes the virus-specific receptor attached, as well as endocytosis, of the target cells [170].…”

Section: Disadvantages Of Neutralizing Antibodies: Antibody-dependent...mentioning

confidence: 99%

Overview of Neutralizing Antibodies and Their Potential in COVID-19

et al. 2021

Self Cite

View full text Add to dashboard Cite

The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.

show abstract

A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies

Cited by 38 publications

References 92 publications

Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody

Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody

Association of Vaccine Confidence and Hesitancy in Three Phases of COVID-19 Vaccine Approval and Introduction in Japan

Overview of Neutralizing Antibodies and Their Potential in COVID-19

Contact Info

Product

Resources

About